Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

A Weiss, E Lorthiois, L Barys, KS Beyer… - Cancer discovery, 2022 - AACR
Covalent inhibitors of KRASG12C have shown antitumor activity against
advanced/metastatic KRASG12C-mutated cancers, though resistance emerges and …
被引用次数：64 相关文章

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.

A Weiss, E Lorthiois, L Barys, KS Beyer… - Cancer …, 2022 - europepmc.org
Covalent inhibitors of KRAS G12C have shown antitumor activity against
advanced/metastatic KRAS G12C-mutated cancers, though resistance emerges and …
[HTML] nih.gov

[HTML][HTML] Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

A Weiss, E Lorthiois, L Barys, KS Beyer… - Cancer …, 2022 - ncbi.nlm.nih.gov
Covalent inhibitors of KRAS G12C have shown antitumor activity against
advanced/metastatic KRAS G12C-mutated cancers, though resistance emerges and …
[PDF] aacrjournals.org

[PDF][PDF] Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

A Weiss, E Lorthiois, L Barys, KS Beyer… - Cancer Discovery, 2022 - AACR
Covalent inhibitors of KRASG12C have shown antitumor activity against
advanced/metastatic KRASG12C-mutated cancers, though resistance emerges and …

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

A Weiss, E Lorthiois, L Barys, KS Beyer… - Cancer …, 2022 - pubmed.ncbi.nlm.nih.gov
Covalent inhibitors of KRASG12C have shown antitumor activity against
advanced/metastatic KRASG12C-mutated cancers, though resistance emerges and …